Introduction/Background The incidence of cervical cancer in the world is 500 thousand new cases per year. In the structure of mortality from malignant neoplasms in women under 45 years of age, this pathology ranks first.

Objective to study the effectiveness and tolerability of stereotactic radiation therapy in patients with recurrent cervical cancer.

Methodology Retrospective and prospective analysis of 100 case histories of patients for the period 2011–2022 who received therapy for recurrent cervical cancer at the Federal State Budgetary Institution National Medical Research Center named after Acad. E.N. Meshalkin’, immunohistochemical study of angiogenesis with CD34, statistical calculations in the RStudio program (version 2022.07.2+576, USA) in R (version 4.1.3 (2022–03-10), Austria).

Results Relapses of cervical cancer occurred more often after CRT - 62% of patients, after extended Wertheim surgery - 27%.

The highest five-year survival rate was observed in the CRT group - 68%; data on the high effectiveness of stereotactic radiation therapy after three-month follow-up are confirmed by long-term results - five-year survival rate for this group was 62%, three-year survival rate - 73%, one-year mortality rate 6%.

A study of angiogenesis in cervical tissue before and after neoadjuvant chemotherapy in the same patients showed a decrease in the area of blood vessels in the tumor, which indicates the effectiveness of neoadjuvant chemotherapy.

Predictors of mortality in patients with relapses were concomitant cardiovascular pathology (p<0.001), ureterohydronephrosis (p<0.035), CRT (p<0.038), endophytic form of tumor growth (p<0.046), anemia (p<0.051).

Conclusion

1. The most common occurrences were locoregional relapses - 28.9%, local relapses - 25.4%, multiple (several relapse sites at once) - 24.9%, distant metastases - 20.8%.

2. When retrospectively assessing the effectiveness of treatment after 3 months, stereotactic radiation therapy showed significantly higher effectiveness compared to the drug therapy group (p<0.001), the five-year survival rate for this group was 62%

Disclosures No.